Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
32 hedge funds and large institutions have $3.98M invested in Nymox Pharmaceutical Corp in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
10% more funds holding
Funds holding: 29 → 32 (+3)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.01% less ownership
Funds ownership: 1.31% → 1.3% (-0.01%)
9% less capital invested
Capital invested by funds: $4.38M → $3.98M (-$410K)
97% less call options, than puts
Call options by funds: $1K | Put options by funds: $32K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$428K |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$293K |
| 3 |
CL
Croft-Leominster
Baltimore,
Maryland
|
+$136K |
| 4 |
BAS
Brown Advisory Securities
Baltimore,
Maryland
|
+$68.2K |
| 5 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
+$60.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Marathon Capital Management
Hunt Valley,
Maryland
|
-$348K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$314K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$234K |
| 4 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$129K |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
-$76.1K |
NYMX Hedge Fund Activity: Q4 2013 in Review
32 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2013, worth a combined $3.98M — down 9.4% from $4.38M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NYMX positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Shepherd Kaplan Krochuk, opening a new position worth an estimated $428K. The largest seller was Marathon Capital Management, cutting an estimated $348K.
- 32 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2013, up from 29 in Q3 2013.
- Funds reported $3.98M of Nymox Pharmaceutical Corp stock for Q4 2013, down 9.4% quarter-over-quarter.
- 6 funds opened new Nymox Pharmaceutical Corp positions in Q4 2013 and 3 closed out, a net change of +3 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q4 2013 was Shepherd Kaplan Krochuk, an estimated $428K added.
- The largest Nymox Pharmaceutical Corp seller in Q4 2013 was Marathon Capital Management, an estimated $348K sold.
Based on aggregated 13F filings for Q4 2013.